Acute intermittent porphyria: is oseltamivir safe in these patients?
Agustín Pijierro Amador, Alba Suárez Cordero and Pedro Sánchez Risco
DOI: https://doi.org/10.7861/clinmed.2022-0100
Clin Med May 2022 Agustín Pijierro Amador
AUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in internal medicine
Alba Suárez Cordero
BUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in gastroenterology and hepatology
Pedro Sánchez Risco
BUniversity Hospital of Badajoz, Badajoz, Spain
Roles: specialist physician in gastroenterology and hepatology

Article Figures & Data
Tables
Normal Attack After treatment Catecholamines in urine Metanephrine, μg/24h 64–302 516 259 Normetanephrine, μg/24h 162–527 2,212 1,135 3-methoxythyramine, μg/24h 103–404 532 296 Porphyrins in urine Delta-aminolevulinate, μg/g <5 101 41 Porphobilinogen, mg/24h <2 205 124 Uroporphyrin, μg/24h 0–50 2,540 608 Coproporphyrin, μg/24h 0–160 1,306 671
Article Tools
Acute intermittent porphyria: is oseltamivir safe in these patients?
Agustín Pijierro Amador, Alba Suárez Cordero, Pedro Sánchez Risco
Clinical Medicine May 2022, 22 (3) 280-281; DOI: 10.7861/clinmed.2022-0100
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.